Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-30 in Refractory or Recurrent Hodgkin's Disease or ALCL
NCT00079755Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Feb 2004
- Primary completion
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iratumumab in Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), sponsored by Seagen Inc.. Started Feb 2004; status: completed.
02
Drugs
iratumumab
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT00079755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079755.